<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393978</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA</org_study_id>
    <secondary_id>R01DA022221</secondary_id>
    <nct_id>NCT00393978</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania</brief_title>
  <official_title>Quetiapine Plus Topiramate or Placebo for Bipolar Mania &amp; Cannabis Use in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine whether this treatment may be useful for&#xD;
      reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation&#xD;
      therapy for individuals on psychopharmacotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to study the effects (both good and bad) of combining&#xD;
      medicines, called quetiapine and topiramate, for treating your symptoms, and other children&#xD;
      and adolescents' symptoms, of bipolar mania (an illness with periods of elation, excessive&#xD;
      excitement, irritability, high energy, racing thoughts, poor sleep, poor judgment, reckless&#xD;
      behavior). It is estimated that 1% of the population of adolescents in the United States has&#xD;
      bipolar disorder. The purpose of this research study is also to study the effects (both good&#xD;
      and bad) of combining the same two medicines, quetiapine and topiramate, for reducing your&#xD;
      use, and other children and adolescents' use, of cannabis (commonly referred to as &quot;pot&quot;). It&#xD;
      is estimated that 30.5% of adolescents in the United States have used cannabis at least once&#xD;
      in their lifetime. Additionally, the purpose of this research is to look at how bipolar&#xD;
      disorder and cannabis use effects brain chemicals and function.&#xD;
&#xD;
      Quetiapine (marketed under the brand name Seroquel) has been approved by the FDA since 1997&#xD;
      to help adults who suffer from schizophrenia (an illness of feeling, thought, perception and&#xD;
      behavior). On January 12, 2004, the FDA approved quetiapine for the treatment of bipolar&#xD;
      symptoms in adults. As of December 2009, Quetiapine has now been approved by the FDA for use&#xD;
      in adolescents (13-17 years of age) for the treatment of schizophrenia and for the treatment&#xD;
      of manic episodes associated with bipolar I disorder in children and adolescents (10-17 years&#xD;
      of age). Bipolar disorder is an illness characterized by recurrent mood swings including&#xD;
      mania (i.e., periods of elation, excessive excitement, irritability, high energy, racing&#xD;
      thoughts, poor sleep, poor judgment, reckless behavior) and clinical depression (i.e., a&#xD;
      depressed mood, loss of interest in activities and disruption of sleep, appetite and energy).&#xD;
      This study is being carried out to see if quetiapine is effective and safe for treatment of&#xD;
      children and adolescents who have the symptoms of bipolar mania. This study is also being&#xD;
      carried out to see if quetiapine, in combination with topiramate, will further reduce bipolar&#xD;
      mania and reduce cannabis use.&#xD;
&#xD;
      As of December 2, 2009, the US Food and Drug Administration (FDA) approved SEROQUEL&#xD;
      (quetiapine fumarate) tablets for the treatment of schizophrenia in adolescents (13-17 years&#xD;
      of age) as monotherapy, and for the acute treatment of manic episodes associated with bipolar&#xD;
      I disorder in children and adolescents (10-17 years of age), both as monotherapy and as an&#xD;
      adjunct to lithium or divalproex.&#xD;
&#xD;
      Topiramate (marketed under the brand name Topamax) is approved by the U.S. FDA for the&#xD;
      prevention of migraine headaches in adults. The FDA has also approved topiramate for epilepsy&#xD;
      (a seizure disorder) and for use as adjunctive therapy (meaning in combination with other&#xD;
      medicines) for partial onset seizures in adults. Topiramate is not approved by the FDA for&#xD;
      use in adults or for use in children and adolescents who have bipolar disorder. This study is&#xD;
      being done to see if topiramate, in combination with quetiapine, will reduce bipolar mania&#xD;
      and reduce cannabis use.&#xD;
&#xD;
      The FDA has declared research studies with MRI field strengths up to and including 8 Tesla (a&#xD;
      measure of field strength) as non-significant risk. This research study uses an MRI with a&#xD;
      field strength of 4 Tesla.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Joints Per Week</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percent Days of Cannabis Use Per Week</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in percent days of cannabis use per week from baseline to week 16.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Cannabis-Related Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Quetiapine and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine and Topiramate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quetiapine and Topiramate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine and placebo</intervention_name>
    <description>placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
    <arm_group_label>Quetiapine and Placebo</arm_group_label>
    <other_name>quetiapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine and Topiramate</intervention_name>
    <description>topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
    <arm_group_label>Quetiapine and Topiramate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria Inclusion Criteria: To be included, all subjects must…&#xD;
&#xD;
          -  have an authorized parent/legal guardian who understands the nature of the study and&#xD;
             who provides written informed consent if the study subject is younger than 18 years of&#xD;
             age. Additionally, each subject must provide assent to the study;&#xD;
&#xD;
          -  be fluent in English;&#xD;
&#xD;
          -  be 12 to 21 years of age, inclusive;&#xD;
&#xD;
          -  be using a medically accepted means of contraception (i.e., oral contraceptives and&#xD;
             barrier methods (diaphragm or condom), medroxyprogesterone acetate injectable&#xD;
             suspension, abstinence) if female and of menarche. Oral contraceptives alone are not&#xD;
             acceptable means of contraception because concomitant use of topiramate and low&#xD;
             estrogen oral contraceptive pills may lead to oral contraceptive failure;&#xD;
&#xD;
          -  have a diagnosis of bipolar I disorder in a current manic or mixed episode, in&#xD;
             addition to a cannabis use disorder (which includes abuse or dependence) within 28&#xD;
             days prior to screening, as determined by the WASH-U-KSADS;&#xD;
&#xD;
          -  have an initial YMRS total score of &gt;16 at screening and baselines;&#xD;
&#xD;
          -  use cannabis a minimum of twice per week on average during the 28 days prior to&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria: Subjects will not be eligible for participation if they…&#xD;
&#xD;
          -  have a known history of mental retardation;&#xD;
&#xD;
          -  are acutely intoxicated, and thus impaired;&#xD;
&#xD;
          -  have manic or depressive symptoms resulting entirely from acute medical illness or&#xD;
             acute intoxication or withdrawal from drugs or alcohol, as determined by medical&#xD;
             evaluation and rapid symptom resolution;&#xD;
&#xD;
          -  have clinically significant alcohol or other drug withdrawal symptoms, as determined&#xD;
             by vital signs, The Clinical Institute Withdrawal Assessment for Alcohol Scale -&#xD;
             Revised (CIWA-Ar)24, and physician interview;&#xD;
&#xD;
          -  have any unstable medical or neurological illness as determined by a study physician;&#xD;
&#xD;
          -  have laboratory abnormalities &gt;3 times upper limits of established normal values;&#xD;
&#xD;
          -  as females, have a positive serum (screening and week 16) or urine pregnancy test (at&#xD;
             baseline and weeks 1-16), are lactating, or are not practicing a reliable form of&#xD;
             birth control;&#xD;
&#xD;
          -  have a history of nephrolithiasis, since topiramate has been associated with an&#xD;
             elevated risk of kidney stones;&#xD;
&#xD;
          -  require concurrent treatment with mood stabilizers, anticonvulsants, or&#xD;
             antidepressants&#xD;
&#xD;
          -  require concurrent treatment with carbonic anhydrase inhibitors.&#xD;
&#xD;
          -  have significant suicidal ideation&#xD;
&#xD;
          -  have been treated for a substance use disorder during 28 days prior to screening or&#xD;
             are court-ordered to treatment for substance use to ensure that, if we detect a change&#xD;
             in use with topiramate treatment, it is likely not due to these other confounding&#xD;
             factors that might influence substance use. Peer support groups are not considered&#xD;
             treatment for substance use. **Patients can be enrolled into the study that are&#xD;
             already enrolled in a court ordered substance treatment, for at least 1 month prior to&#xD;
             study enrollment, if they still meet the minimum cannabis use criterion.**&#xD;
&#xD;
          -  have been diagnosed or treated for an eating disorder, to make sure any weight loss&#xD;
             does not contribute to an already underlying condition&#xD;
&#xD;
          -  have a family history of glaucoma, since topiramate has been associated with an&#xD;
             elevated risk of glaucoma;&#xD;
&#xD;
          -  have a history of non-response or hypersensitivity to quetiapine or topiramate;&#xD;
&#xD;
          -  if scanning, have claustrophobia and/or contraindicated for magnetic resonance&#xD;
             scanning (i.e. intraocular metallic objects, braces, cochlear implants, pacemakers, or&#xD;
             other electrical, mechanical, or magnetically activated implants); and&#xD;
&#xD;
          -  if scanning, have a history of significant head trauma (i.e. injury resulting in loss&#xD;
             of consciousness for greater than five minutes).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa P DelBello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-0516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 30, 2006</study_first_submitted>
  <study_first_submitted_qc>October 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2006</study_first_posted>
  <results_first_submitted>May 16, 2016</results_first_submitted>
  <results_first_submitted_qc>July 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 29, 2017</results_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Melissa Delbello</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar mania</keyword>
  <keyword>Cannabis consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quitiapine + Placebo</title>
          <description>Quetiapine + Placebo&#xD;
quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine + Topiramate</title>
          <description>Quetiapine + Topiramate&#xD;
Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quitiapine + Placebo</title>
          <description>Quetiapine + Placebo&#xD;
quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
        </group>
        <group group_id="B2">
          <title>Quetiapine + Topiramate</title>
          <description>Quetiapine + Topiramate&#xD;
Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="2.1"/>
                    <measurement group_id="B2" value="17.7" spread="2.1"/>
                    <measurement group_id="B3" value="17.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Joints Per Week</title>
        <description>Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quitiapine and Placebo</title>
            <description>Quetiapine and Placebo&#xD;
Quetiapine and placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine and Topiramate</title>
            <description>Quetiapine and Topiramate&#xD;
Quetiapine and Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Joints Per Week</title>
          <description>Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.</description>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="27.2"/>
                    <measurement group_id="O2" value="-10.7" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent Days of Cannabis Use Per Week</title>
        <description>Change in percent days of cannabis use per week from baseline to week 16.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quitiapine and Placebo</title>
            <description>Quetiapine and Placebo&#xD;
Quetiapine and placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine and Topiramate</title>
            <description>Quetiapine and Topiramate&#xD;
Quetiapine and Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Days of Cannabis Use Per Week</title>
          <description>Change in percent days of cannabis use per week from baseline to week 16.</description>
          <units>cannabis use</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="41.1"/>
                    <measurement group_id="O2" value="-43.5" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over a period of 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quitiapine + Placebo</title>
          <description>Quetiapine + Placebo&#xD;
quetiapine + placebo: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).</description>
        </group>
        <group group_id="E2">
          <title>Quetiapine + Topiramate</title>
          <description>Quetiapine + Topiramate&#xD;
Quetiapine + Topiramate: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Exacerbation of illness</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Increased Suicidal Ideation</sub_title>
                <description>Increased suicidal ideation during hospitalization</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty falling asleep</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Difficulty staying asleep</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Excitement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa P. DelBello, MD</name_or_title>
      <organization>University of Cincinnati, Department of Psychiatry &amp; Behavioral Neuroscience</organization>
      <phone>513-558-2989</phone>
      <email>Melissa.DelBello@uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

